Replies to post #237289 on Biotech Values

[DewDiligence]

LLY acquires MORF for $57/sh cash—a 79% premium to Friday’s closing price:

https://finance.yahoo.com/news/lilly-acquire-morphic-improve-outcomes-104500467.html

MORF’s lead drug is MORF-057, an oral small-molecule drug in phase-2 for UC and Crohn’s disease.

The nominal deal value is $3.2B.